CNBX.US Cannabics Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.0001 USD
Close of Nov 12, 2026
0.0001 0.0007
Market cap
USD 161K
P/E
-
P/B
20.39x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is CNBX.US undervalued?

Graham number

The Graham number of Cannabics Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cannabics Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Cannabics Pharmaceuticals Inc yet.

Cannabics Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cannabics Pharmaceuticals Inc

CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or s…

Full company profile